Sarepta muscular dystrophy drug SRP-9001 endorsed by FDA advisors Posted on May 12, 2023 By Charlielikes Stock Market
Sarepta stock -20% on FDA advisory meeting for its muscular dystrophy treatment Posted on March 16, 2023 By Charlielikes Stock Market